Orthopedic Biomaterial Market is estimated to be valued at USD 18.96 Bn in 2025 and is expected to reach USD 36.71 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.
The Orthopedic Biomaterial Market Size is experiencing robust growth due to advancements in biomaterial technologies and also product innovations. The market for orthopedic biomaterials is expanding rapidly due to factors such as the growing need for orthopedic implants, the prevalence of musculoskeletal conditions, and the rise in trauma and sports-related injuries.
For instance, in September 2024, Temple OrthoBiologics, a new venture spun out from women’s health company Temple Therapeutics, is proud to announce its official launch heralding a breakthrough in orthopedic sports medicine. For years, the prevention of scar tissue was considered impossible. Temple OrthoBiologics is changing that narrative.
|
Event |
Description and Impact |
|
Surge in Orthopedic Surgeries |
|
|
Aging Population & Chronic Skeletal Conditions |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Based on material type, the glass-ceramic & bioactive glasses contribute the 41.2% share of the market owing to its superior properties and advantages over other biomaterials. Their superior mechanical strength and controlled degradation make them ideal for implants and bone regeneration, offering distinct advantages over polymers and metals in clinical applications.
Based on application, the joint replacement contributes the highest share of the market, this is attributed to the rising cases of osteoarthritis and musculoskeletal disorders globally. Aging populations and sedentary lifestyles contribute to joint degeneration, driving demand for advanced biomaterials that enhance implant durability, biocompatibility, and patient outcomes in hip, knee, and shoulder replacements.
Based on end user, the hospitals contribute the highest share of the market, owing to the high volume of orthopedic procedures like joint replacement, spinal fusion, and orthopedic biomaterial for Bone Fixation performed at inpatient facilities. Their advanced infrastructure, skilled personnel, and access to cutting-edge biomaterials make them the primary setting for complex orthopedic interventions, driving their leading market share
To learn more about this report, Download Free Sample
North America is estimated to hold a dominant position in the global orthopedic biomaterial market over the forecast period. North America is estimated to hold 44.60% of the market share in 2025. The North America region is expected to dominate the global orthopedic biomaterial market over the forecast period.
The presence of major medical device manufacturers in the U.S. is a key factor driving growth in this region. The U.S. is home to large multinational corporations like Johnson & Johnson, Stryker, Zimmer Biomet, and Medtronic, all medical technology companies which together account for over 80% of the orthopedic biomaterial market in the region.
Moreover, increasing acquisitions between market players are expected to drive the market growth in the region. For instance, in September 2023, Restor3d, the U.S.-based manufacturer of 3D-printed orthopedic implants, announced the completion of its previously announced acquisition of restor3d, a company that manufactures customized knee and hip replacements. Restor3d provides patient-specific, patient-matched, and auxiliary goods. Its specialty is in 3D printing osseointegrative biomedical materials.
Europe region is anticipated to be the fastest growing region in the orthopedic biomaterials market. The region’s growth is underpinned by a robust healthcare infrastructure, a high volume of orthopedic surgeries, and strong emphasis on research and development leading to innovative treatment options. European countries benefit from widespread adoption of advanced biomaterials for joint replacements, fracture fixation, and other orthopedic applications.
The U.S. benefits from advanced healthcare infrastructure, strong reimbursement frameworks, and significant investments in research and development, which drive the adoption of innovative biomaterial products. The presence of major industry players and a focus on minimally invasive procedures further support the country’s leadership in this sector.
Due to its huge and increasingly aging population, increased incidence of bone degenerative disorders, and rising healthcare costs, India is becoming one of the Asia Pacific region's fastest-growing markets for orthopedic biomaterials. Due to an increase in joint replacement surgeries and the rising number of trauma and sports injuries, the nation is seeing a strong demand for orthopedic implants and biomaterials.
China is a major contributor to the growth of the worldwide orthopedic biomaterials market because of its large population, fast urbanization, and increasing musculoskeletal disease prevalence. The country is experiencing increased demand for orthopedic implants and biomaterials, supported by expanding healthcare infrastructure and government policies aimed at modernizing medical services.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 18.96 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.9% | 2032 Value Projection: | USD 36.71 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
B. Braun Melsungen AG, CONMED Corp., Evonik Industries AG, Medtronic Plc., Smith & Nephew Plc., Stryker Corp., Victrex Plc. (Invibio Ltd.), and Zimmer Biomet Holdings Inc., Globus Medical, Heraeus Holding GmbH, Exactech Inc., Collagen Matrix Inc., Koninklijke DSM N.V., DePuy Synthes. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Mergers and acquisitions are reshaping the Orthopedic Biomaterial Market, driving innovation and expanding market share. In 2025, leading companies like Zimmer Biomet, Heraeus Medical, and Keensight Capital executed strategic acquisitions to enhance their biomaterial portfolios and technological capabilities. These deals aim to integrate advanced regenerative solutions and robotic technologies, fueling growth and competitiveness. As consolidation intensifies, it strengthens global distribution networks and accelerates product development, ultimately influencing the Orthopedic Biomaterial Market share across joint reconstruction, orthobiologics, and spinal applications.
Additionally, innovations such as 3D printing, nanotechnology, and biofabrication are enabling the development of personalized orthopedic implants tailored to individual patient anatomy and needs. These technologies facilitate the creation of complex, bone-mimicking structures with superior mechanical properties and bioactivity, improving both integration and long-term outcomes for patients.
Nanotechnology, in particular, is being leveraged to produce implants with enhanced surface features that mimic natural bone, promote better cell attachment, and reduce infection risk, addressing some of the limitations of traditional materials.
The rising prevalence of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and osteoporosis is a major driver propelling the growth of the global orthopedic biomaterial market. For instance, according to the Centers for Disease Control and Prevention (CDC), June 2023, 1 in 4 (or 53.2 million) U.S. adults had some form of arthritis in 2021. While there are estimated to be more than 100 types of arthritis, osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million U.S. adults.
The aging population and obesity epidemic have significantly contributed to the increasing musculoskeletal disease burden. With life expectancy rising globally, the World Health Organization (WHO) report for 2022 estimates that the population aged 60 years or older will increase from 1 billion in 2020 to 1.4 billion by 2030.
Since advanced age is a prominent risk factor for osteoarthritis, osteoporosis, and other musculoskeletal conditions, the exponential growth of the elderly demographic will lead to a higher disease burden and greater demand for orthopedic treatments involving biomaterials.
Continual advances in orthopedic biomaterials and implant designs are driving market expansion by improving clinical outcomes and the longevity of implants. Active research is underway to develop innovative biomaterials like porous titanium, biodegradable polymers, and 3D printed constructs that can better integrate with native bone, stimulate bone regeneration, and reduce stress shielding compared to traditional metal implants.
For instance, in July 2023, Himed, a biomaterials company located in the U.S., and Lithoz, a worldwide industry leader in 3D printing based in Austria, announced a collaboration to create novel bioceramic feedstocks. The two companies have entered into a long-term strategic materials research partnership agreement to investigate novel integrations of Himed's calcium phosphate (CaP) biomaterials with Lithoz's proprietary ceramic binder utilized in their cutting-edge CeraFab S65 medical 3D printer.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
